Pharmacological enhancement of anti-inflammatory drug efficacy through solid lipid nanoparticles in osteoarthritis and rheumatoid arthritis: a review
Authors:
Open Access
- 23 March 2026
- journal article
- review article
- Published by Springer Nature in Inflammopharmacology
- Vol. 34 (4) , 2043-2060
Abstract
Chronic inflammatory diseases, such as rheumatoid arthritis and osteoarthritis, are sustained by dysregulated cytokine signaling, eicosanoid production, and the continuous activation of intracellular inflammatory pathways. Although nonsteroidal anti-inflammatory drugs, corticosteroids, and disease-modifying drugs are foundational treatments, their long-term use is limited due to unfavorable pharmacokinetics, lack of tissue selectivity, and systemic side effects. Solid lipid nanoparticles (SLNs) have emerged as a promising delivery system. They serve as lipid carriers, enabling better control of drug distribution while preserving pharmacodynamic effects. Preclinical studies indicate that SLN formulations can enhance the pharmacokinetics of anti-inflammatory drugs by promoting local retention, providing extended release, and increasing local drug exposure at sites of inflammation following topical, intra-articular, or systemic administration. At the molecular level, drugs delivered using SLNs consistently inhibit key inflammatory mediators, including TNF-α, IL-1β, IL-6, and PGE₂. These actions are associated with reduced activation of nuclear factor-κB and Janus kinase/signal transducer and activator of transcription pathways, as well as decreased oxidative stress and leukocyte accumulation in inflamed joints and surrounding tissues. Importantly, SLNs do not change the inherent action of the drugs they carry; instead, they enhance their pharmacological effectiveness by prolonging drug concentration at the target site and reducing exposure to non-target tissues. This fine-tuning of pharmacokinetics can lead to dose-saving strategies, which are particularly vital in the long-term management of arthritis. SLNs are an active delivery system that improves the performance of anti-inflammatory drugs by modulating controlled exposure and altering molecular pathways. However, further prolonged dosing studies and clinical trials are necessary to fully establish their clinical utility. Graphical abstractKeywords
Funding Information
- Manipal Academy of Higher Education, Manipal
This publication has 40 references indexed in Scilit:
- Targeted counteracting of overactive macrophages by melittin stable-loaded solid lipid nanoparticles alleviates cytokine storm and acute inflammatory injuryBiomedicine & Pharmacotherapy, 2024
- N-trimethyl chitosan and tripalmitin loaded solid lipid nanoparticles of tofacitinib citrate: Characterization and in-vivo anti-inflammatory assessmentJournal of Drug Delivery Science and Technology, 2023
- Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis managementMaterials Today Bio, 2023
- Development of ibuprofen-loaded solid lipid nanoparticle-based hydrogels for enhanced in vitro dermal permeation and in vivo topical anti-inflammatory activityJournal of Drug Delivery Science and Technology, 2020
- Effect of the Ratio of Betamethasone to TNF-α siRNA Coencapsulated in Solid Lipid Nanoparticles on the Acute Proinflammatory Activity of the NanoparticlesMolecular Pharmaceutics, 2019
- Formulation of topical ibuprofen solid lipid nanoparticle (SLN) gel using hot melt extrusion technique (HME) and determining its anti-inflammatory strengthDrug Delivery and Translational Research, 2019
- Intra-articular delivery of a methotrexate loaded nanostructured lipid carrier based smart gel for effective treatment of rheumatic diseasesRSC Advances, 2016
- Cartilage damage in osteoarthritis and rheumatoid arthritis—two unequal siblingsNature Reviews Rheumatology, 2015
- The Pathogenesis of Rheumatoid ArthritisNew England Journal of Medicine, 2011
- Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old DrugsNew England Journal of Medicine, 2005